[go: up one dir, main page]

SMT201600383B - 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia - Google Patents

1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia

Info

Publication number
SMT201600383B
SMT201600383B SM201600383T SM201600383T SMT201600383B SM T201600383 B SMT201600383 B SM T201600383B SM 201600383 T SM201600383 T SM 201600383T SM 201600383 T SM201600383 T SM 201600383T SM T201600383 B SMT201600383 B SM T201600383B
Authority
SM
San Marino
Prior art keywords
schizofrenia
indani
fenil
piperazino
deuterated
Prior art date
Application number
SM201600383T
Other languages
English (en)
Inventor
Klaus Gjervig Jensen
Lassina Badolo
Mette Graulund Hvenegaard
Mikkel Fog Jacobsen
Morten Jorgensen
Peter Hongaard Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SMT201600383B publication Critical patent/SMT201600383B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SM201600383T 2011-06-20 2016-10-26 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia SMT201600383B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21
PCT/IB2012/001386 WO2012176066A1 (en) 2011-06-20 2012-06-19 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
SMT201600383B true SMT201600383B (it) 2017-01-10

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20190179T SMT201900179T1 (it) 2011-06-20 2012-06-19 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia
SM201600383T SMT201600383B (it) 2011-06-20 2016-10-26 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20190179T SMT201900179T1 (it) 2011-06-20 2012-06-19 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia

Country Status (41)

Country Link
US (8) US8575174B2 (it)
EP (4) EP2720989B1 (it)
JP (1) JP5668177B2 (it)
KR (2) KR101939546B1 (it)
CN (1) CN103649019B (it)
AP (1) AP3310A (it)
AR (1) AR086987A1 (it)
AU (1) AU2012273657B2 (it)
BR (1) BR112013031702B1 (it)
CA (1) CA2837820C (it)
CL (1) CL2013003646A1 (it)
CO (1) CO6821965A2 (it)
CR (1) CR20130654A (it)
CY (2) CY1118158T1 (it)
DK (2) DK3135656T3 (it)
DO (1) DOP2013000305A (it)
EA (1) EA024651B1 (it)
EC (1) ECSP14013155A (it)
ES (3) ES2939477T3 (it)
GE (1) GEP201706655B (it)
GT (1) GT201300304A (it)
HK (1) HK1197228A1 (it)
HR (2) HRP20161348T1 (it)
HU (2) HUE030883T2 (it)
IL (1) IL229640B (it)
JO (1) JO3128B1 (it)
LT (2) LT2720989T (it)
MA (1) MA35268B1 (it)
MD (1) MD4538C1 (it)
ME (2) ME03375B (it)
MX (1) MX339552B (it)
MY (1) MY196998A (it)
PE (2) PE20141113A1 (it)
PH (1) PH12013502598A1 (it)
PL (2) PL3135656T3 (it)
PT (2) PT3135656T (it)
RS (2) RS58546B1 (it)
SI (2) SI3135656T1 (it)
SM (2) SMT201900179T1 (it)
TW (3) TWI614234B (it)
WO (1) WO2012176066A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03375B (me) 2011-06-20 2020-01-20 H Lundbeck As Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
PT3679018T (pt) 2017-09-07 2022-04-05 Otsuka Pharma Co Ltd Processo industrial de monoalquilação de um nitrogénio de piperidina em derivados de piperidina com alquilo deuterado
WO2020089147A1 (en) * 2018-10-29 2020-05-07 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
EA202191731A1 (ru) * 2018-12-21 2021-10-28 Консерт Фармасьютикалз, Инк. Дейтерированные формы и производные волинансерина
CA3132953A1 (en) * 2019-03-13 2020-09-17 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196284A (en) 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
AU599580B2 (en) 1984-12-04 1990-07-26 Sandoz Ag Indene analogs of mevalonolactone
WO2010037398A1 (en) 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2536144C (en) 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
RS20060083A (en) * 2003-08-18 2008-08-07 H.Lundbeck A/S., Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
CA2597620A1 (en) 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
BRPI0615973A2 (pt) 2005-07-29 2011-05-31 Concert Pharmaceuticals Inc novos derivados de benzo [d] [1,3] - dioxol
JP5302005B2 (ja) 2005-12-01 2013-10-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド セロトニン作動性および／またはノルエピネフリン作動性の活性を有する置換フェネチルアミン
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
PT2003120E (pt) 2007-06-12 2010-02-11 Concert Pharmaceuticals Inc Derivados de azapéptido como inibidores de protease de hiv
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
EA018927B1 (ru) 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
KR20110110097A (ko) 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
EP2362865A2 (en) 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2639216B1 (en) 2010-11-09 2018-07-11 Kaneka Corporation Halogenated indenones and method for producing optically active indanones or optically active indanols by using same
JP2014501771A (ja) 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
CN109608436B (zh) 2011-04-08 2022-10-11 斯法尔制药私人有限公司 取代的甲基甲酰基试剂及使用所述试剂改进化合物物理化学和/或药代动力学性质的方法
ME03375B (me) 2011-06-20 2020-01-20 H Lundbeck As Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije
WO2014055938A1 (en) 2012-10-04 2014-04-10 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
EP3135656B1 (en) 2019-02-27
ES2719145T3 (es) 2019-07-08
BR112013031702B1 (pt) 2021-11-03
JP2014520140A (ja) 2014-08-21
HUE044043T2 (hu) 2019-09-30
US12116355B2 (en) 2024-10-15
CR20130654A (es) 2014-03-24
WO2012176066A1 (en) 2012-12-27
AP2013007338A0 (en) 2013-12-31
US20150307458A1 (en) 2015-10-29
PT3135656T (pt) 2019-05-03
HK1197228A1 (zh) 2015-01-09
TW201311248A (zh) 2013-03-16
SI3135656T1 (sl) 2019-05-31
MX339552B (es) 2016-05-31
US10501427B2 (en) 2019-12-10
US10118907B2 (en) 2018-11-06
CY1121514T1 (el) 2020-05-29
PT2720989T (pt) 2016-11-07
CA2837820A1 (en) 2012-12-27
EA024651B1 (ru) 2016-10-31
DK2720989T3 (en) 2016-11-28
US9216961B2 (en) 2015-12-22
US20190031631A1 (en) 2019-01-31
DK3135656T3 (en) 2019-04-23
AU2012273657A1 (en) 2013-12-12
CA2837820C (en) 2019-02-19
PE20141113A1 (es) 2014-09-25
ME02513B (me) 2017-02-20
JO3128B1 (ar) 2017-09-20
MA35268B1 (fr) 2014-07-03
EP3508468A1 (en) 2019-07-10
IL229640A0 (en) 2014-01-30
ME03375B (me) 2020-01-20
HUE030883T2 (en) 2017-06-28
HRP20190593T1 (hr) 2019-05-17
ECSP14013155A (es) 2014-02-28
HRP20161348T1 (hr) 2016-12-02
RS55304B1 (sr) 2017-03-31
US20120322811A1 (en) 2012-12-20
RS58546B1 (sr) 2019-05-31
US9012453B2 (en) 2015-04-21
BR112013031702A2 (pt) 2016-12-13
US11059798B2 (en) 2021-07-13
CY1118158T1 (el) 2017-06-28
MD20140004A2 (en) 2014-05-31
TW201902481A (zh) 2019-01-16
AR086987A1 (es) 2014-02-05
LT3135656T (lt) 2019-04-25
IL229640B (en) 2018-02-28
EP3135656A1 (en) 2017-03-01
KR20180075717A (ko) 2018-07-04
SI2720989T1 (sl) 2016-11-30
GT201300304A (es) 2015-01-16
EP4215512A1 (en) 2023-07-26
KR101879474B1 (ko) 2018-07-17
EP2720989B1 (en) 2016-08-10
TW201722895A (zh) 2017-07-01
TWI627956B (zh) 2018-07-01
US8575174B2 (en) 2013-11-05
MD4538C1 (ro) 2018-07-31
NZ618222A (en) 2015-03-27
ES2601213T3 (es) 2017-02-14
US20130281436A1 (en) 2013-10-24
US9617231B2 (en) 2017-04-11
KR20140041567A (ko) 2014-04-04
AU2012273657B2 (en) 2016-07-21
EP2720989A1 (en) 2014-04-23
PE20150928A1 (es) 2015-06-26
US20220119362A1 (en) 2022-04-21
KR101939546B1 (ko) 2019-01-16
JP5668177B2 (ja) 2015-02-12
PL2720989T3 (pl) 2017-05-31
EP3508468B1 (en) 2023-01-18
PL3135656T3 (pl) 2019-07-31
TWI659741B (zh) 2019-05-21
TWI614234B (zh) 2018-02-11
US20160068497A1 (en) 2016-03-10
US20170158650A1 (en) 2017-06-08
SMT201900179T1 (it) 2019-05-10
DOP2013000305A (es) 2014-02-28
MD4538B1 (ro) 2017-12-31
GEP201706655B (en) 2017-04-25
LT2720989T (lt) 2016-11-25
CO6821965A2 (es) 2013-12-31
MX2013014849A (es) 2014-03-31
CN103649019A (zh) 2014-03-19
ES2939477T3 (es) 2023-04-24
EA201490045A1 (ru) 2014-07-30
PH12013502598A1 (en) 2014-02-10
MY196998A (en) 2023-05-17
CN103649019B (zh) 2015-09-16
AP3310A (en) 2015-06-30
US20200131143A1 (en) 2020-04-30
CL2013003646A1 (es) 2014-07-04

Similar Documents

Publication Publication Date Title
HK1244183A1 (zh) Ivacaftor的氘化衍生物
SMT201600129B (it) Trattamento della lipodistrofia
SMT201600383B (it) 1–piperazino–3–fenil indani deuterati per il trattamento della schizofrenia
HUE047354T2 (hu) Ivacaftor deuterizált származékai
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
PL2739153T3 (pl) Leczenie raka sutka
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
IL231092A0 (en) Treatment of rhinitis
EP2750709A4 (en) TREATMENT OF KACHEXIE
EP2709665A4 (en) TREATMENT OF PSORIASIS
IL229005A0 (en) Pyrazolidin - 3 - one derivatives
EP2739764A4 (en) ION SOURCE
SMT201500119B (it) Nuova composizione per il trattamento della trombocitemia essenziale
IL228486A0 (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201309613B (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
GB201118065D0 (en) Treatment of movement disorders
ITTO20110655A1 (it) Strumento per il massaggio delle gengive
UA22461S (uk) Деталь фасонна компресійна-цанга